Nektar Therapeutics (BMV:NKTR)
Mexico · Delayed Price · Currency is MXN | Market Cap | 40.16B +1,717.8% |
| Revenue (ttm) | 1.00B -36.2% |
| Net Income | -2.85B |
| EPS | -145.87 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5 |
| Average Volume | 175 |
| Open | 1,584.15 |
| Previous Close | 1,701.34 |
| Day's Range | 1,584.15 - 1,584.15 |
| 52-Week Range | 165.00 - 1,742.00 |
| Beta | n/a |
| RSI | 65.03 |
| Earnings Date | May 7, 2026 |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has col... [Read more]
Financial Performance
In 2025, Nektar Therapeutics's revenue was $55.23 million, a decrease of -43.89% compared to the previous year's $98.43 million. Losses were -$164.08 million, 37.9% more than in 2024.
Financial numbers in USD Financial StatementsNews
Nektar price target lowered to $80 from $95 at Wedbush
Wedbush analyst Martin Fan lowered the firm’s price target on Nektar (NKTR) to $80 from $95 and keeps a Neutral rating on the shares. The firm notes the company reported…
Nektar Therapeutics Q1 Earnings Call Highlights
Nektar Therapeutics NASDAQ: NKTR outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 fin...
Nektar price target raised to $192 from $105 at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Nektar (NKTR) to $192 from $105 and keeps an Overweight rating on the shares. The firm notes the company…
Nektar Therapeutics Earnings Call Transcript: Q1 2026
REZPEG showed strong efficacy and durability in phase IIb studies for atopic dermatitis and alopecia areata, supporting phase III trials in both. Financials remain robust with over $1 billion in cash, funding operations through key milestones.
Nektar Therapeutics Earnings release: Q1 2026
Nektar Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Nektar Therapeutics Quarterly report: Q1 2026
Nektar Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)
Reports Q1 revenue $10.86M, consensus $10.69M. “2026 is shaping up to be a defining year for Nektar (NKTR) and for our lead biologic candidate rezpegaldesleukin,” said Howard Robin, President and…
Nektar Therapeutics Reports First Quarter 2026 Financial Results
SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable securities...
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors grante...
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based finan...
Nektar Therapeutics Proxy statement: Proxy filing
Nektar Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Nektar Therapeutics Proxy statement: Proxy filing
Nektar Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closi...
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap...
Nektar price target raised to $95 from $70 at Wedbush
Wedbush raised the firm’s price target on Nektar (NKTR) to $95 from $70 and keeps a Neutral rating on the shares. The firm notes Nektar reported deepening responses in 52-week…
Nektar price target raised to $151 from $123 at Citi
Citi raised the firm’s price target on Nektar (NKTR) to $151 from $123 and keeps a Buy rating on the shares. The firm cites the positive alopecia areata data for…
Nektar announces $250M common stock offering
Nektar (NKTR) Therapeutics announced that it has commenced an underwritten public offering of $250M of its shares of its common stock and, in lieu of common stock to certain investors,…
Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap...
This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness.
Nektar Therapeutics releases positive results from its trial for the treatment of alopecia areata.
Nektar price target raised to $185 from $165 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nektar (NKTR) to $185 from $165 and keeps a Buy rating on the shares after the company reported “strong” 16-week treatment extension…
Nektar Therapeutics Transcript: Study update
The 52-week REZOLVE-AA phase II-B extension showed rezpeg led to significant, durable hair regrowth in severe alopecia areata, with a favorable safety profile and no new safety signals. Experts expect rezpeg to become a first-line therapy, shifting treatment away from JAK inhibitors.
Nektar Therapeutics Press release: Study update
Nektar Therapeutics issued a press release on April 20, 2026, disclosing material business information to investors.
Nektar Therapeutics Slides: Study update
Nektar Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 20, 2026.